Pirsidomine
Pirsidomine is a nitric oxide donor. Pirsidomine is a sydnonimine compound. Pirsidomine can transform into a nitric oxide-releasing metabolite in vivo. Pirsidomine prevents occlusion-induced increase in flow in the non-occluded circumflex coronary artery and significantly reduces the blood flow in non-ischemic areas in myocardial infarction dog model. Pirsidomine can be studied in research on cardiovascular diseases[1][2].
Product Specifications
CAS Number
132722-74-8
UNSPSC
12352005
Target
Endogenous Metabolite
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Smiles
C[C@H]1N([N+]2=NOC([N-]C(C3=CC=C(OC)C=C3)=O)=C2)[C@H](CCC1)C
Molecular Formula
C17H22N4O3
Molecular Weight
330.38
References & Citations
[1]Martorana, P. A., et al., (1994) . Antiischemic effects of pirsidomine, a new nitric oxide donor. European journal of pharmacology, 257 (3), 267-273. |[2]Stengele, E., et al., (1996) . Short-term hemodynamic, anti-ischemic, and antianginal effects of pirsidomine, a new sydnonimine. The American journal of cardiology, 77 (11), 937-941.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LCC31690-01 250 mg
2- (Dodecylsulfanyl) -3,4-dihydroquinazolin-4-one
Sign In for Pricing
View Details LCC31690-02 2.5 g
2- (Dodecylsulfanyl) -3,4-dihydroquinazolin-4-one
Sign In for Pricing
View Details 
MBS9305067-01 48 Well
Rat Leukotriene B4 receptor 1, LTB4R ELISA Kit
Sign In for Pricing
View Details